PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING EFFICACY AND SAFETY OF MOSUNETUZUMAB IN COMBINATION WITH LENALIDOMIDE IN COMPARISON TO RITUXIMAB IN COMBINATION WITH LENALIDOMIDE WITH A NON RANDOMIZED SINGLE ARM US EXTENSION OF MOSUNETUZUMAB IN COMBINATION WITH LENALIDOMIDE IN PATIENTS WITH FOLLICULAR LYMPHOMA AFTER AT LEAST ONE LINE OF SYSTEMIC THERAPY

Brief description of study

This is a Phase III, open-label, multicenter, randomized controlled trial in patients with R/R FL after receiving at least 1 line of systemic therapy. Patients with FL will be randomized in a 1:1 ratio to receive either M + Len or R + Len.


Clinical Study Identifier: s21-00033
ClinicalTrials.gov Identifier: NCT04712097
Principal Investigator: Catherine M Diefenbach.
Other Investigators: Kenneth B Hymes, Marc Justin Braunstein, Maxim Kreditor, Bruce G Raphael, Michael L. Grossbard, John Leslie Vaughn, Ellaine R Yap, Shella Saint Fleur-Lominy, David Kaminetzky, Tibor Moskovits, Bonnie Kiner-Strachan, Thaleshravi Prashad.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.